$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000143774922011776 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$1.888M	$2.559M
YoY Change	-26.22%	13.18%
Cost Of Revenue	$1.364M	$1.665M
YoY Change	-18.08%	-5.4%
Gross Profit	$524.0K	$894.0K
YoY Change	-41.39%	78.44%
Gross Profit Margin	27.75%	34.94%
Selling, General & Admin	$4.148M	$3.945M
YoY Change	5.15%	-10.05%
% of Gross Profit	791.6%	441.28%
Research & Development	$1.072M	$1.598M
YoY Change	-32.92%	0.25%
% of Gross Profit	204.58%	178.75%
Depreciation & Amortization	$15.00K	$194.0K
YoY Change	-92.27%	-13.78%
% of Gross Profit	2.86%	21.7%
Operating Expenses	$5.220M	$5.543M
YoY Change	-5.83%	-7.31%
Operating Profit	-$4.696M	-$4.649M
YoY Change	1.01%	-15.15%
Interest Expense	$439.0K	$396.0K
YoY Change	10.86%	-0.5%
% of Operating Profit
Other Income/Expense, Net	-$5.000K	-$7.000K
YoY Change	-28.57%	75.0%
Pretax Income	-$5.140M	-$5.050M
YoY Change	1.78%	-13.68%
Income Tax
% Of Pretax Income
Net Earnings	-$5.140M	-$5.052M
YoY Change	1.74%	-13.66%
Net Earnings / Revenue	-272.25%	-197.42%
Basic Earnings Per Share	-$2.33	-$1.33
Diluted Earnings Per Share	-$1.051M	-$55.23K
COMMON SHARES
Basic Shares Outstanding	4.889M	4.572M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.01M	$30.45M
YoY Change	-34.3%	208.82%
Cash & Equivalents	$20.00M	$30.45M
Short-Term Investments
Other Short-Term Assets	$1.315M	$1.320M
YoY Change	-0.38%	29.41%
Inventory	$5.350M	$3.936M
Prepaid Expenses
Receivables	$1.365M	$1.531M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$28.04M	$37.23M
YoY Change	-24.7%	131.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$230.0K	$552.0K
YoY Change	-58.33%	-60.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$406.0K	$476.0K
YoY Change	-14.71%	-25.27%
Total Long-Term Assets	$3.576M	$4.876M
YoY Change	-26.66%	-27.08%
TOTAL ASSETS
Total Short-Term Assets	$28.04M	$37.23M
Total Long-Term Assets	$3.576M	$4.876M
Total Assets	$31.61M	$42.11M
YoY Change	-24.93%	84.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.172M	$786.0K
YoY Change	49.11%	-43.25%
Accrued Expenses	$816.0K	$856.0K
YoY Change	-4.67%	23.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$2.070M
YoY Change		-77.91%
Total Short-Term Liabilities	$6.007M	$7.235M
YoY Change	-16.97%	-49.97%
LONG-TERM LIABILITIES
Long-Term Debt	$12.73M	$11.32M
YoY Change	12.43%
Other Long-Term Liabilities	$719.0K	$144.0K
YoY Change	399.31%	1340.0%
Total Long-Term Liabilities	$719.0K	$144.0K
YoY Change	399.31%	1340.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.007M	$7.235M
Total Long-Term Liabilities	$719.0K	$144.0K
Total Liabilities	$21.38M	$21.63M
YoY Change	-1.16%	17.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$389.9M	-$372.4M
YoY Change	4.7%	5.14%
Common Stock	$400.1M	$392.9M
YoY Change	1.85%	9.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.23M	$20.48M
YoY Change
Total Liabilities & Shareholders Equity	$31.61M	$42.11M
YoY Change	-24.93%	84.69%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$5.140M	-$5.052M
YoY Change	1.74%	-13.66%
Depreciation, Depletion And Amortization	$15.00K	$194.0K
YoY Change	-92.27%	-13.78%
Cash From Operating Activities	-$6.181M	-$4.803M
YoY Change	28.69%	-3.36%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	$11.00K
YoY Change	181.82%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$31.00K	-$11.00K
YoY Change	181.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.721M	$13.08M
YoY Change	-48.6%	236.26%
NET CHANGE
Cash From Operating Activities	-$6.181M	-$4.803M
Cash From Investing Activities	-$31.00K	-$11.00K
Cash From Financing Activities	$6.721M	$13.08M
Net Change In Cash	$509.0K	$8.263M
YoY Change	-93.84%	-864.38%
FREE CASH FLOW
Cash From Operating Activities	-$6.181M	-$4.803M
Capital Expenditures	$31.00K	$11.00K
Free Cash Flow	-$6.212M	-$4.814M
YoY Change	29.04%	-3.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5454849
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5454849
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4778263
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4778263
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	58851
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20006000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19497000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5679849
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	58851
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	58851
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	USD
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1394000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1365000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1393000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	5350000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1315000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	28036000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	25791000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2940000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	230000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	406000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	420000	USD
CY2022Q1	us-gaap	Assets Assets	31612000	USD
CY2021Q4	us-gaap	Assets Assets	29485000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1172000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1881000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1609000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1044000	USD
CY2022Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	1127000	USD
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	816000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	718000	USD
CY2022Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	5111000	USD
CY2021Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	-0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11378000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6096000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.33
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4889000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4572000
CY2021Q1	us-gaap	Interest Expense InterestExpense	396000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5052000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1127000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1011000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6007000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4706000	USD
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12727000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12287000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1929000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	719000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	575000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	21382000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	19762000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	400118000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	394380000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-389893000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384753000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10230000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31612000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29485000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1888000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2559000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1364000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	1665000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	524000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	894000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1072000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1598000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4148000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3945000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5220000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	5543000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4696000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4649000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	439000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1044000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13076000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13077000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	418000	USD
CY2021Q1	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5052000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	144000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	144000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6181000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4803000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	20475000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	USD
CY2022Q1	avgr	Stock Issued During Period Value Reverse Stock Split Fractional Shares StockIssuedDuringPeriodValueReverseStockSplitFractionalShares	0	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1127000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10230000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5052000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	194000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	52000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	418000	USD
CY2022Q1	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	419000	USD
CY2021Q1	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	370000	USD
CY2022Q1	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	24000	USD
CY2021Q1	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	34000	USD
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	8000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	7000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-28000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	49000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	67000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1015000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	968000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-223000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	272000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-135000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	98000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	187000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6721000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13077000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	509000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8263000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19497000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22185000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20006000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30448000	USD
CY2021Q1	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-34000	USD
CY2022Q1	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-24000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">1.</em> Organization</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Organization, Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <em style="font: inherit;"> March 2007. </em>The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<em style="font: inherit;"> “OCT”) </em>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, our Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liquidity Matters</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <em style="font: inherit;"> March 31, 2022, </em>the Company had an accumulated deficit of $389.9 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $20.0 million at <em style="font: inherit;"> March 31, 2022 </em>and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations into the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em> The Company received net proceeds of approximately $6.7 million net proceeds from the <em style="font: inherit;"> January 2022 </em>Series D preferred stock equity financing and $13.0 million from the sale of its common stock in <em style="font: inherit;"> February 2021. </em>The Company <em style="font: inherit;"> may </em>decide to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company can provide <em style="font: inherit;">no</em> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <em style="font: inherit;">not</em> create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company <em style="font: inherit;"> may </em>undertake in the next <em style="font: inherit;">twelve</em> months could cause substantial dilution to its existing stockholders, and there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. In addition, the COVID-<em style="font: inherit;">19</em> pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <em style="font: inherit;"> may </em>have to significantly reduce its operations or delay, scale back or discontinue the development and sale of <em style="font: inherit;">one</em> or more of its products. The financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> September 22, 2021, </em>the Company received a letter from Nasdaq’s Listing Qualifications Department notifying it that it was <em style="font: inherit;">not</em> in compliance with Nasdaq Listing Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>), as the minimum bid price for its listed securities was less than <em style="font: inherit;">$1</em> for the previous <em style="font: inherit;">30</em> consecutive business days. The Company had a period of <em style="font: inherit;">180</em> calendar days, or until <em style="font: inherit;"> March 21, 2022, </em>to regain compliance with the rule referred to in this paragraph. The Company did <em style="font: inherit;">not</em> regain compliance with the minimum bid price requirement by <em style="font: inherit;"> March 21, 2022. </em>In accordance with Nasdaq Listing Rule <em style="font: inherit;">5810</em>(c)(<em style="font: inherit;">3</em>)(A), the Company provided written notice to Nasdaq of its intent to cure the deficiency and, on <em style="font: inherit;"> March 22, 2022, </em>the Company received notice that Nasdaq granted the Company an additional <em style="font: inherit;">180</em> calendar days, or until <em style="font: inherit;"> September 19, 2022, </em>to regain compliance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> March 29, 2022, </em>the Company received a letter from Nasdaq notifying the Company that the Staff had determined that the closing bid price of the Company’s common stock had been at <em style="font: inherit;">$1.00</em> per share or greater for at least <em style="font: inherit;">10</em> consecutive business days and, accordingly, that the Company had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market and that the matter is now closed. While the Company has regained compliance with the minimum bid price requirement, there can be <em style="font: inherit;">no</em> assurance that the Company will be able to maintain compliance with the minimum bid price requirement in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Public Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Past Offerings</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> February 2, 2021, </em>under the shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><em style="font: inherit;"> January 2022 </em>Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 14, 2022, </em>the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (<em style="font: inherit;"> “January 2022 </em>Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which is convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In connection with the <em style="font: inherit;"> January 2022 </em>Offering and in accordance with the securities purchase agreement, the Company held a special meeting of stockholders on <em style="font: inherit;"> March 11, 2022 </em>to consider a proposal (the “Proposal”) to amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”) to effect a reverse split of the outstanding shares of the Company’s common stock at a ratio between <em style="font: inherit;">1</em>-for-5 and <em style="font: inherit;">1</em>-for-20 (the “Reverse Split Amendment”). The Company’s stockholders approved the Reverse Split Amendment at the special meeting. On <em style="font: inherit;"> March 11, 2022, </em>following receipt of stockholder approval, the Company’s Board of Directors approved a reverse split ratio of <em style="font: inherit;">1</em>-for-20 and the Company filed an amendment to the Company’s Charter to effect such reverse stock split, effective as of <em style="font: inherit;">5:00</em> pm Eastern Time on <em style="font: inherit;"> March 14, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to the purchase agreement, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of Series D preferred stock, which became effective on <em style="font: inherit;"> January 14, 2022. </em>The Certificate of Designation provided, in particular, that the Series D preferred stock will have <em style="font: inherit;">no</em> voting rights, other than the right to vote as a class on certain matters, except that each share of Series D preferred stock had the right to cast 37,500 votes per share of Series D preferred stock on the Proposal (the “Supermajority Voting Rights”); provided, that the votes cast by the holders of the Series D preferred stock must be counted in the same proportion as the aggregate shares of common stock voted on the Proposal. Because the Proposal was approved by our stockholders at the special meeting held on <em style="font: inherit;"> March 11, 2022, </em>the Series D preferred stock <em style="font: inherit;">no</em> longer has Supermajority Voting Rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The holders of the Series D preferred stock are entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Series D preferred stock is convertible into shares of common stock at a conversion price of $8.00 per share, as adjusted for the most recent reverse stock split. The conversion price can be adjusted pursuant to the Certificate of Designation for stock dividends and stock splits, subsequent rights offerings, pro rata distributions of dividends or the occurrence of a fundamental transaction (as defined in the Certificate of Designation). The Series D preferred stock can be converted at the option of the holders at any time. In addition, subject to the satisfaction of certain conditions, the Company <em style="font: inherit;"> may </em>cause the holders of the Series D preferred stock to convert their shares of Series D preferred stock; provided, that shares of Series D preferred stock cannot be converted to common stock if the applicable holder would beneficially own in excess of <em style="font: inherit;">4.99%</em> (or, upon election by such holder prior to the issuance of any shares of Series D preferred stock, <em style="font: inherit;">9.99%</em>) of our outstanding common stock. A holder of Series D preferred stock <em style="font: inherit;"> may, </em>upon notice to the Company, increase or decrease such beneficial ownership limitation, but <em style="font: inherit;">not</em> in excess of <em style="font: inherit;">9.99%.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The 807,500 Common Warrants have an exercise price of $9.60 per share and become exercisable beginning <em style="font: inherit;"> July 14, 2022. </em>The Common Warrants will expire <span style="-sec-ix-hidden:c84080537">five</span> years following the time they become exercisable, or <em style="font: inherit;"> July 14, 2027. </em>The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of <span style="-sec-ix-hidden:c84080540">five</span> years from the commencement of the sales pursuant to the <em style="font: inherit;"> January 2022 </em>Offering, or <em style="font: inherit;"> January 12, 2027.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q1	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	1127000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1831000	USD
CY2021Q1	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	1044000	USD
CY2022Q1	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	118000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2097000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-389900000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20000000.0	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <em style="font: inherit;"> may </em>undertake in the future, actual results <em style="font: inherit;"> may </em>ultimately materially differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q1	us-gaap	Inventory Net InventoryNet	5350000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	USD
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	187000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	193000	USD
CY2022Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	4000	USD
CY2021Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	20000	USD
CY2022Q1	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	20000	USD
CY2021Q1	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	2000	USD
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	171000	USD
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	211000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11378000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6096000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4889000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4572000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.33
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	944007
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	161699
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2530000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3179000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2503000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	989000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2940000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	274000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2940000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
CY2022Q1	avgr	Operating Lease Expense Excluding Maintenance Fee And Other Expense Monthly OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly	105000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	66000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	59000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	264000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	249000	USD
CY2022Q1	us-gaap	Prepaid Rent PrepaidRent	150000	USD
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	158000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	873000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1203000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1138000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3214000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2940000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2940000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1011000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1929000	USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	58851
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2022Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	5111000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5454849
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26456895
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	43936895
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1006285
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1006285
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q1	us-gaap	Share Price SharePrice	3.63
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	418000	USD

Files In Submission

Name	View Source	Status
0001437749-22-011776-index-headers.html	Edgar Link	pending
0001437749-22-011776-index.html	Edgar Link	pending
0001437749-22-011776.txt	Edgar Link	pending
0001437749-22-011776-xbrl.zip	Edgar Link	pending
avgr-20220331.xsd	Edgar Link	pending
avgr-20220331_cal.xml	Edgar Link	unprocessable
avgr-20220331_def.xml	Edgar Link	unprocessable
avgr-20220331_lab.xml	Edgar Link	unprocessable
avgr-20220331_pre.xml	Edgar Link	unprocessable
avgr20220331_10q.htm	Edgar Link	pending
avgr20220331_10q_htm.xml	Edgar Link	completed
ex_370853.htm	Edgar Link	pending
ex_370854.htm	Edgar Link	pending
ex_370855.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2022 Q1 Form 10-Q Financial Statement

#000143774922011776 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2022 Q1 Form 10-Q Financial Statement

#000143774922011776 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr